Literature DB >> 19493905

Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.

Yasushi Adachi1, Rong Li, Hiroyuki Yamamoto, Yongfen Min, Wenhua Piao, Yu Wang, Arisa Imsumran, Hua Li, Yoshiaki Arimura, Choon-Taek Lee, Kohzoh Imai, David P Carbone, Yasuhisa Shinomura.   

Abstract

Insulin-like growth factor-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of gastrointestinal (GI) cancers. We have previously shown significant therapeutic activity for recombinant adenoviruses expressing dominant-negative insulin-like growth factor-I receptor (IGF-IR/dn), including suppression of tumor invasion. In this study, we sought to evaluate the mechanism of inhibition of invasion and the relationship between IGF-IR and matrix metalloproteinase (MMP) activity in GI carcinomas. We analyzed the role of IGF-IR on invasion in three GI cancer cell lines, colorectal adenocarcinoma, HT29; pancreatic adenocarcinoma, BxPC3 and gastric adenocarcinoma, MKN45, using a modified Boyden chamber method and subcutaneous xenografts in nude mice. The impact of IGF-IR signaling on the expression of MMPs and the effects of blockade of matrilysin or IGF-IR on invasiveness were assessed using recombinant adenoviruses, a tyrosine kinase inhibitor NVP-AEW541 and antisense matrilysin. Invasive subcutaneous tumors expressed several MMPs. IGF-IR/dn reduced the expression of these MMPs but especially matrilysin (MMP-7). Insulin-like growth factor (IGF) stimulated secretion of matrilysin and IGF-IR/dn blocked IGF-mediated matrilysin induction in three GI cancers. Both IGF-IR/dn and inhibition of matrilysin reduced in vitro invasion to the same degree. NVP-AEW541 also reduced cancer cell invasion both in vitro and in murine xenograft tumors via suppression of matrilysin. Thus, blockade of IGF-IR is involved in the suppression of cancer cell invasion through downregulation of matrilysin. Strategies of targeting IGF-IR may have significant therapeutic utility to prevent invasion and progression of human GI carcinomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19493905     DOI: 10.1093/carcin/bgp134

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  20 in total

1.  MMP-9 is increased in the pathogenesis of gastric cancer by the mediation of HER2.

Authors:  Y-Q Shan; R-C Ying; C-H Zhou; A-K Zhu; J Ye; W Zhu; T-F Ju; H-C Jin
Journal:  Cancer Gene Ther       Date:  2015-01-30       Impact factor: 5.987

Review 2.  Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.

Authors:  Tolutope Oyasiji; Jianliang Zhang; Boris Kuvshinoff; Renuka Iyer; Steven N Hochwald
Journal:  Oncologist       Date:  2015-05-29

3.  A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers.

Authors:  Yasushi Adachi; Hiroyuki Yamamoto; Hirokazu Ohashi; Takao Endo; David-P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

Review 4.  Molecular targeted approaches for treatment of pancreatic cancer.

Authors:  Z Q Huang; A K Saluja; V Dudeja; S M Vickers; D J Buchsbaum
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 5.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 6.  Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials.

Authors:  Omar Abdel-Rahman
Journal:  Med Oncol       Date:  2014-12-09       Impact factor: 3.064

7.  Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer.

Authors:  Taketsugu Yamamoto; Takashi Oshima; Kazue Yoshihara; Teppei Nishi; Hiromasa Arai; Kenji Inui; Takeshi Kaneko; Akinori Nozawa; Hiroyuki Adachi; Yasushi Rino; Munetaka Masuda; Toshio Imada
Journal:  Exp Ther Med       Date:  2012-02-22       Impact factor: 2.447

Review 8.  An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa.

Authors:  Hiroyuki Yamamoto; Yoshiyuki Watanabe; Tadateru Maehata; Ryo Morita; Yoshihito Yoshida; Ritsuko Oikawa; Shinya Ishigooka; Shun-Ichiro Ozawa; Yasumasa Matsuo; Kosuke Hosoya; Masaki Yamashita; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Hiroshi Yasuda; Yasuhisa Shinomura; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

9.  Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.

Authors:  Koji Numata; Takashi Oshima; Kentaro Sakamaki; Kazue Yoshihara; Toru Aoyama; Tsutomu Hayashi; Takanobu Yamada; Tsutomu Sato; Haruhiko Cho; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Chikara Kunisaki; Makoto Akaike; Toshio Imada; Munetaka Masuda
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-03       Impact factor: 4.553

10.  Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.

Authors:  Samuel Wolf; Jana Lorenz; Joachim Mössner; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.